Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
3,527
Views
6
CrossRef citations to date
0
Altmetric
Neurology

Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database

Regina Berkovicha Los Angeles USC General Hospital and Clinic, Los Angeles, CA, USA
,
Edward Foxb Central Texas Neurology Consultants, Round Rock, TX, USA
,
Annette Okaic Multiple Sclerosis Treatment Center of Dallas, Dallas, TX, USA
,
Yao Dingd IQVIA, Inc., Collegeville, PA, USAORCID Iconhttps://orcid.org/0000-0002-5415-3024
ORCID Icon,
Magdaliz Gorritzd IQVIA, Inc., Collegeville, PA, USAORCID Iconhttps://orcid.org/0000-0001-6806-3188
ORCID Icon,
Lauren Bartolomee Jefferson College of Population Health, Philadelphia, PA, USA;f Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Rolin L. Waded IQVIA, Inc., Collegeville, PA, USAORCID Iconhttps://orcid.org/0000-0003-3634-1504
ORCID Icon,
Wendy Suf Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Kristen M. Johnsonf Novartis Pharmaceuticals Corporation, East Hanover, NJ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1767-2957
ORCID Icon &
Patricia Russof Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
 show all
Pages 46-53 | Received 08 Sep 2020, Accepted 18 Nov 2020, Published online: 18 Dec 2020

References

  • Hempel S, Estrada E, Chen A, et al. Modifiable risk factors in the progression of multiple sclerosis: a systematic review of the epidemiology and treatment. VA evidence-based synthesis program reports. Washington (DC): Department of Veterans Affairs (US); 2015.
  • Bansi J, Bloch W, Gamper U, et al. Training in MS: influence of two different endurance training protocols (aquatic versus overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial. Mult Scler. 2013;19(5):613–621.
  • Wallin MT, Culpepper WJ, Nichols E, et al. (GBD 2016 Multiple Sclerosis Collaborators). Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269–285.
  • Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71(2):129–135.
  • Adelman G, Rane SG, Villa KF, et al. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639–647.
  • Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics. 2009;27(8):681–691.
  • Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord. 2010;3(4):229–239.
  • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452.
  • Munsell M, Frean M, Menzin J, et al. Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs. BMC Neurol. 2017;17(1):106.
  • Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in health care claims. J Med Econ. 2010;13(4):616–625.
  • Moran JL, Solomon PJ, Peisach AR, et al. New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract. 2007;13(3):381–389.
  • Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004;9(4):197–204.
  • Li Z, Mahendra G. Using ‘recycled predictions’ for computing marginal effects. Proceedings of the SAS® Global Forum 2010 Conference. Cary, NC: SAS Institute, Inc.; 2010.
  • Guan W. From the help desk: bootstrapped standard errors. Stata J. 2003;3(1):71–80.
  • Jones E, Pike J, Marshall T, et al. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US. BMC Health Serv Res. 2016;16(1):294.
  • Kobelt G, Berg J, Atherley D, et al. Costs and quality of life in multiple sclerosis. SSE/EFI Working Paper Series in Economics and Finance No. 594; 2004. p. 1–34.
  • Lipsy RJ, Schapiro RT, Prostko CR. Current and future directions in MS management: key considerations for managed care pharmacists. J Manag Care Pharm. 2009;15(9 Suppl. A):S2–S15.
  • Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J. 2017;23(8):1123–1136.
  • Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169–178.
  • Lonergan R, Kinsella K, Duggan M, et al. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started? Mult Scler. 2009;15(12):1528–1531.
  • Costello K, Halper J, Kalb R, et al. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence; 2020; [cited 2020 Apr 24]. Available from: https://www.mscare.org/page/dmt
  • Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet. 2018;391(10127):1263–1273.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.